Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

information fournie par Boursorama CP •26/05/2023 à 07:30

Presentations include new data further demonstrating the immune responses induced by TG4001 and recently updated results from the adjuvant Phase I trial of neoantigen vaccine TG4050 in head and neck cancer

Strasbourg, France, May 26, 2023, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced two poster presentations at the 2023 American Association of Clinical Oncology (ASCO) annual meeting to be held in Chicago, IL (June 2-6).

The posters will highlight that in challenging clinical settings:
- TG4001 induced T-cell responses against HPV16 antigens in the ongoing Phase II trial.
- TG4050: 100% of the patients treated with the individualized therapeutic cancer vaccine developed multiple functional T cell responses against targeted neoantigens, which may be associated with an improved outcome in patients with head and neck cancer in the adjuvant setting.

.../...